Adoptive cellular immunotherapy with CD19-specific T cells

Claudia Rössig, S. Pscherer, S. Landmeier, B. Altvater, H. Jürgens, J. Vormoor

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

25 Citaten (Scopus)


Background: No effective therapeutic modalities exist for the treatment of relapsed high risk acute lymphoblastic leukemia (ALL). Adoptive cellular immunotherapy by transfusion of polyclonal donor lymphocytes is not always effective and is limited by cellular cross-reactivity with normal tissues, leading to development of clinical graft-versus-host disease (GVHD). Method: To develop an immunotherapeutic strategy for targeted elimination of residual leukemic blasts, human T cells were gene-modified to express CD19-specific chimeric receptors. Results: Gene-modified T cells specifically lyse CD19-expressing lymphatic blast cells, however, they show a limited proliferative response to stimulation with CD19. Integration of the signal transduction domain of the costimulatory molecule CD28 enhances the proliferative properties of the gene-modified T cells. Conclusions: Adoptive transfer of gene-modified virus-specific T cells may provide a useful strategy for prevention and early treatment of ALL relapses following allogeneic stem cell transplantation.

Originele taal-2Engels
Pagina's (van-tot)351-356
Aantal pagina's6
TijdschriftKlinische Padiatrie
Nummer van het tijdschrift6
StatusGepubliceerd - nov. 2005
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Adoptive cellular immunotherapy with CD19-specific T cells'. Samen vormen ze een unieke vingerafdruk.

Citeer dit